Biosimilar brand buy to help Intas Pharma take on biggies

In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NPaOJ0H
via IFTTT